Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • UK: NICE rejects...

    UK: NICE rejects Johnson and Johnson nasal spray for depression in NHS

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-01-29T12:38:28+05:30  |  Updated On 29 Jan 2020 12:38 PM IST
    UK: NICE rejects Johnson and Johnson nasal spray for depression in NHS

    The National Institute for Health and Care Excellence (NICE), which determines if a drug is included in Britain's National Healthcare System (NHS), said there was a lack of evidence on how the treatment, chemically called esketamine, fared over rivals, and that it could raise costs.

    Britain's healthcare cost agency on Tuesday recommended against including Johnson & Johnson's nasal spray for depression, Spravato, in the country's healthcare network, citing uncertainties over its clinical and cost-effectiveness.

    The National Institute for Health and Care Excellence (NICE), which determines if a drug is included in Britain's National Healthcare System (NHS), said there was a lack of evidence on how the treatment, chemically called esketamine, fared over rivals, and that it could raise costs.

    In the draft guidance, NICE also questioned the effects of stopping the treatment, saying it was unclear if any improvement in symptoms would be maintained after a course, potentially adding to costs.

    "Introduction of esketamine into clinical practice in the NHS will be complex because the structure and delivery of services would need to be changed," said Meindert Boysen, director of the centre for health technology evaluation at NICE.

    NHS currently manages treatment-resistant depression with oral medicines, followed by a second drug if symptoms do not improve. Sometimes the state-run health service combines drugs with psychological therapy.

    Esketamine is approved as a combination therapy for adults with a major depressive disorder who have not benefited from prior treatments.

    It is chemically a mirror image of the anaesthetic ketamine that is often abused under the street name "Special K", and hence requires that it be given under the supervision of a healthcare professional in a clinic.

    "Estimates of the costs of providing the clinical service for esketamine were highly uncertain, as are the costs of repeated courses of the drug," Boysen said.

    In the United States, the spray is priced here at $590 for a 56 mg dose and $885 for 84 mg.

    Esketamine received approvals from European and U.S. regulators last year, marking a new type of antidepressant in over 30 years and raising hopes for its relatively fast action to treat patients failed by prior treatments.

    More than 264 million people of all ages suffer from depression worldwide, according to here to the World Health Organization.

    Read also: J&J CEO Alex Gorsky to testify at trial for first time on Baby Powder risks

    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok